Abstract
Background Chronic Obstructive Pulmonary Disease (COPD) and Idiopathic Pulmonary Fibrosis (IPF) are chronic, progressive lung ailments which are characterized by distinct pathologies. Early detection biomarkers and disease mechanisms for these debilitating diseases are lacking. Exosomes are small extracellular vesicles attributed to carry proteins, mRNA, miRNA and sncRNA to facilitate cell-to-cell communication under normal and diseased conditions. Exosomal miRNAs have been studied in relation to many diseases. However, there is little to no knowledge regarding the miRNA population of BALF or the lung tissue derived exosomes in COPD and IPF. Here, we determined and compared the miRNA profiles of BALF and lung tissue-derived exosomes from healthy non-smokers, healthy smokers, and patients with COPD and IPF in independent cohorts.
Results Exosome characterization using NanoSight particle tracking and TEM demonstrated that the BALF-derived exosomes were approximately 89.85 nm in size and ∼2.95 × 1010 particles/mL. Lung-derived exosomes were ∼146.04 nm in size and ∼2.38 × 1011 particles/mL. NGS results identified three differentially expressed miRNAs in the BALF, while one in the lung-derived exosomes from COPD patients as compared to healthy non-smokers. Of these, three- and five-fold downregulation of miR-122-5p amongst the lung tissue-derived exosomes from COPD patients as compared to healthy non-smokers and smokers, respectively. Interestingly, there were key 55 differentially expressed miRNAs in the lung tissue-derived exosomes of IPF patients compared to non-smoking controls.
Conclusions Overall, we identified specific miRNAs to develop as biomarkers or targets for pathogenesis of these chronic lung diseases.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
Not applicable
Funding Statement
The National Institutes of Health (NIH) HL137738, HL133404 and HL135613 supported this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The procurement of human lung tissues and BALF samples as deidentified samples was approved by the Materials Transfer Agreement and Procurement (Institutional Review Board, IRB), and Laboratory protocols by the Institutional Biosafety Committee (IBC) at the University of Rochester Medical Center, Rochester, NY. The project codes and dates of approval were as follow: Project Code: DRAI1 001 Protocol: 004, Date of approval and IRB/IBC approvals 2/11/2017 and 9/29/2017. All the procedures/ protocols were carried per the guidelines and regulations specified by the University of Rochester, Rochester, NY. Other approvals include: (a) IRB study number 20080326 at the University of Miami, and (b) registered clinical trial (NCT04016181) and ethically approved by the University of Edinburgh (07/S1102/20) and NHS Lothian 2007/R/RES/02 by 14/06/2007. Additional samples were obtained from baseline measurements of Feasibility of Retinoids for the Treatment of Emphysema (FORTE) trial participants as described previously.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
List of Abbreviations
- COPD
- Chronic Obstructive Pulmonary disease
- IPF
- Idiopathic Pulmonary disease
- TEM
- Transmission Electron Microscopy
- NGS
- Next Generation sequencing miRNA: micro RNA
- BALF
- Bronchoalveolar Lavage fluid
- EMT
- epithelial-mesenchymal transition
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos